Pancreatic Cancer Research

ResearcherCapital Medical UniversityActive in the last 2 years

Xiaoqing Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6959-8667; OpenAlex author ID A5100734034. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jare.2025.10.079↗
  2. Integrated analysis of Dendrobium nobile extract Dendrobin A against pancreatic ductal adenocarcinoma based on network pharmacology, bioinformatics, and valida… Co-author DOI 10.3389/fphar.2023.1079539↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wentong Mei · 1 shared paper, 2026 · strength 0.27
  2. Yixuan Ding · 1 shared paper, 2026 · strength 0.27
  3. Yuchen Jia · 1 shared paper, 2026 · strength 0.27
  4. Fei Li · 1 shared paper, 2026 · strength 0.27
  5. Banzhan Ruan · 1 shared paper, 2023 · strength 0.17
  6. Shaojiang Zheng · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.